| Name | Title | Contact Details |
|---|
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
Osco Drug is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
United Drugs is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Leiters is a FDA-registered 503B outsourcing provider of high quality ophthalmology and hospital-based services. We are committed to providing healthcare professionals and their patients with high quality medications.